Evaluación de la percepción de las barreras en la asistencia sanitaria y del impacto de las inyecciones intravítreas en la degeneración macular asociada a la edad neovascular

  1. J.I. Fernández-Vigo 12
  2. B. Burgos-Blasco 1
  3. C. Calvo-González 1
  4. M.J. Escobar 1
  5. H. Shi 1
  6. M. Jiménez-Santos 1
  7. A. Valverde-Megías 1
  8. J. Reche-Frutos 1
  9. L. López-Guajardo 1
  10. J. Donate-López 1
  1. 1 Hospital Clínico San Carlos de Madrid
    info

    Hospital Clínico San Carlos de Madrid

    Madrid, España

    ROR https://ror.org/04d0ybj29

  2. 2 Centro Internacional de Oftalmología Avanzada, Madrid, España
Journal:
Archivos de la Sociedad Española de Oftalmologia

ISSN: 0365-6691

Year of publication: 2022

Volume: 97

Issue: 4

Pages: 198-204

Type: Article

DOI: 10.1016/J.OFTAL.2021.02.005 DIALNET GOOGLE SCHOLAR

More publications in: Archivos de la Sociedad Española de Oftalmologia

Abstract

Aim To evaluate the perception of barriers in healthcare and the impact of intravitreal injections in patients with neovascular age-related macular degeneration (nAMD). Methods Cross-sectional study including 108 patients with nAMD in treatment with intravitreal injections. The patients answered a questionnaire with 26 questions (score from 1 to 5) divided in three sections: 1) the disease and its treatment with injections; 2) healthcare barriers, and 3) new technologies. Results The mean age was 80.4 ± 7.0 years and visual acuity (VA) was 75.2 ± 12.4 letters. The main barriers in healthcare were long waiting times (72%), followed by other comorbidities (10%). Some 63% of patients have to wait between 3 and 5 hours to attend their clinical visit. Significant anxiety due to the injections (2.8 ± 1.3) was observed, being present in 71% of the cases the day before. A great fear of blindness and losing independence was observed (4.4 ± 0.9 and 4.3 ± 1.1), with no differences in relation to VA, age or sex (P ≥ .135). Moreover, 28% of the patients reported that it was quite or very difficult for them to attend the clinical visit, with 69% of the total showing great interest in having a diagnostic device at home. Conclusion The nAMD and its treatment represent a significant burden on patients, among whom there is a great fear of blindness and of losing their independence, the main barrier being the long waiting time for the clinical visit.

Data source: Dialnet